Noa Therapeutics is developing non-steroidal, multimodal small molecules that target three distinct drivers of inflammatory barrier diseases, utilizing a computer-assisted drug discovery engine. This approach aims to improve treatment efficacy and safety for conditions like atopic dermatitis, addressing the limitations of current therapies that primarily focus on symptom relief.
Funding
$366.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JCMOFounders
Product
Problem
Current treatments for inflammatory barrier diseases primarily focus on symptom relief, often addressing individual disease drivers in isolation. This can lead to limited efficacy, poor patient compliance, and significant side effects, resulting in a cycle of trial-and-error treatment failures.
Solution
Noa Therapeutics is developing non-steroidal, multimodal small molecules designed to simultaneously target multiple drivers of inflammatory barrier diseases. Utilizing a computer-assisted drug discovery engine, Noa aims to create singular therapeutic solutions that address the complexity of immune diseases involving barrier dysfunction. Their lead drug compound, NOA-104, is designed to restore barrier function, promote immune homeostasis, and modulate the microbiome without compromising systemic immunity. This approach seeks to improve treatment outcomes and safety profiles, particularly for underrepresented and underserved patient populations, including juvenile and pediatric patients.
Target Audience
The primary target audience includes individuals affected by inflammatory barrier diseases, such as atopic dermatitis, and the physicians who treat them, with a particular focus on underrepresented and underserved patients, including juvenile and pediatric populations.
Features
- Non-steroidal, multimodal small molecules with tunable activity across three inflammatory barrier disease drivers
- Computer-assisted drug discovery engine for tailored treatment of immune diseases
- Targets immune modulation by attenuating inflammatory cytokines and promoting immune homeostasis
- Focuses on barrier restoration by upregulating epithelial and endothelial barrier proteins
- Aims for microbiome modulation with broad-spectrum antimicrobial efficacy while retaining a null resistance profile
- Lead drug compound, NOA-104, targeting atopic dermatitis as a first use case
- Potential expansion into secondary dermatological inflammatory diseases and systemic inflammatory disease markets